Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

588 results about "Antigen epitope" patented technology

An epitope, also known as antigenic determinant, is the part of an antigen that is recognized by an antibody, B-cell receptor or T-cell receptor. Generally an antigen has several or many different epitopes and reacts with many different antibodies, an epitope is approximately five or six amino acids in length. Adjuvant.

Porcine transmissible gastroenteritis virus epitope vaccine as well as preparation method and application thereof

ActiveCN119823287AAntiviralsAntibody medical ingredientsAntigen epitopeSwine Transmissible Gastroenteritis
The invention relates to the technical field of biology, in particular to a swine transmissible gastroenteritis virus epitope vaccine and a preparation method and application thereof, the amino acid sequence of FliCS.T-TGEV-S fusion protein is shown as SEQ ID NO.3, and the nucleotide sequence of the FliCS.T-TGEV-S fusion protein is shown as SEQ ID NO.4. The fusion protein FliCS.T-TGEV-S prepared by the invention is used as an epitope vaccine based on dominant antigen epitopes of TGEV, and combines advanced means such as immunodominant epitopes, a fusion protein technology and genetic engineering, so that the specificity and the protection effect of the vaccine are enhanced. The vaccine not only can induce high-level antibody response and effectively inhibit TGEV infection, but also has relatively high safety and stability. Compared with a traditional vaccine, the vaccine has remarkable advantages in the aspects of production cost, immune efficacy, protection durability and the like, and a feasible TGE prevention and control scheme is provided for the pig industry.
Owner:YANGZHOU UNIV

Preparation of antibody capable of detecting multi-subtype KPC and application of kit of antibody

The invention discloses preparation of an antibody capable of detecting multi-subtype KPC and application of a kit of the antibody, and belongs to the field of biological medicine. According to the kit for detecting the common subtypes of KPC and the application of the kit, the mouse antibodies are prepared through immunization of conserved antigen epitopes of all the subtypes of KPC, in-vitro screening and pairing are carried out in multiple modes, then an antibody pair which is good in specificity and high in affinity and can be combined with multiple subtypes is obtained, the titer of the two antibodies can reach one million or above, and the kit is high in specificity, good in affinity and capable of being used for detecting the common subtypes of KPC. Amino acid sequences of a heavy chain variable region and a light chain variable region are obtained through sequencing, and rapid and stable expression can be realized after recombination. The product for detecting the carbapenem KPC is developed on the basis of an immunochromatography platform, and the kit has the advantages of high sensitivity, good specificity, good stability, capability of covering most epidemic KPC subtypes and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.
Owner:JIANGSU MEDOMICS MEDICAL TECHNOLOGY CO LTD

Porcine reproductive and respiratory syndrome virus N protein antigen epitope peptide and monoclonal antibody and application thereof

The invention discloses a porcine reproductive and respiratory syndrome virus N protein antigen epitope peptide and a monoclonal antibody thereof. The amino acid sequence of the antigen epitope peptide is as shown in SEQ ID No. 11; the heavy chain variable region of the monoclonal antibody comprises CDR1-3 as shown in SEQ ID No.1 to SEQ ID No.3; the light chain variable region comprises CDR1-3 as shown in SEQ ID No. 4 to 6; the monoclonal antibody reacts with a variety of PRRSV strains such as classical PRRSV, HP-PRRSV, NADC30PRRSV-like, NADC34PRRSV-like, European PRRSV and the like, and the conservative property is good; the antibody can be obtained by biological means such as conventional genetic engineering, and the problem that the genetic sequence of the antibody is easy to lose due to long-term cryopreservation of traditional hybridoma cells is avoided; optimization of the antibody on the gene or protein level is facilitated, and the specificity and affinity of the antibody are further improved.
Owner:LANZHOU UNIV +1

Monoclonal antibody of BRVA virus VP7 protein and epitope and application thereof

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of BRVA virus VP7 protein and an epitope and application of the monoclonal antibody. The invention provides a hybridoma cell strain (preservation number: CCTCC NO: C202570). A monoclonal antibody prepared from the hybridoma cell strain can be combined with VP7 protein of G6, G8 and G10 type BRVA; the antigen epitope amino acid sequence of the monoclonal antibody is SEQ ID NO: 1. The monoclonal antibody and the antigen epitope peptide provided by the invention have broad-spectrum neutralizing activity, and provide a new strategy and tool for prevention and control of BRVA.
Owner:SOUTHWEST UNIVERSITY FOR NATIONALITIES

Chicken infectious anemia virus subunit vaccine

The invention discloses a chicken infectious anemia virus subunit vaccine, and belongs to the technical field of animal disease vaccines. The invention provides a chicken infectious anemia virus subunit vaccine. Active ingredients of the chicken infectious anemia virus subunit vaccine are recombinant fusion protein of chicken infectious anemia virus VP1 protein B cell epitope and salmonella typhimurium flagellin. The B cell epitope of the chicken infectious anemia virus VP1 protein is obtained by connecting B cell antigen epitopes contained in the chicken infectious anemia virus VP1 protein through a connecting peptide. The salmonella typhimurium flagellin is obtained by deleting a hypervariable region of the salmonella typhimurium flagellin FliC. The fusion expression protein provided by the invention can induce generation of a specific IgG antibody after one-day-old SPF chicken, and after immunization for 28 days, immunized chicken flocks can resist challenge of chicken infectious anemia virus virulent strains, and 70% of challenge chicken flocks are protected without disease attack. The invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.
Owner:JINYU YOUBANG BIOTECHNOLOGY (JIANGSU) CO LTD

Above pox virus antigen epitope peptide and application thereof

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.
Owner:THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV +1

Pig acute diarrhea syndrome coronavirus spike protein antigen epitope peptide and monoclonal antibody and application thereof

The invention belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus as well as a monoclonal antibody and application of the spike protein antigen epitope peptide. The invention provides an antibody or an antigen binding fragment thereof. A nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is as shown in SEQ ID NO. 2; the nucleotide sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. The amino acid sequence of the minimum binding epitope is as shown in SEQ ID NO.22. The antigen epitope is highly conserved in a plurality of different subtypes of SADS-CoV. The antibody can be applied to fundamental research on an SADS-CoV invasive molecular mechanism and provides a good scientific research material for application research on SADS-CoV detection and treatment.
Owner:GUANGDONG BIOTECHNOLOGY RESEARCH INSTITUTE (GUANGDONG PROVINCE EXPERIMENTAL ANIMAL MONITORING CENTER)

Method and device for predicting epitope information, medium and program product

The invention aims to provide a method and equipment for predicting antigen epitope information, a medium and a program product, and the method comprises the following steps: respectively determining antigen surface atomic information and antibody surface atomic information based on to-be-docked antigen information and to-be-docked antibody information; based on the antigen surface atomic information and the antibody surface atomic information, respectively determining corresponding antigen block information and antibody block information; and based on the antigen block information and the antibody block information, determining corresponding antigen epitope information by using a corresponding deep learning network. The method focuses on the surface information in the antigen and antibody binding process, the epitope is predicted by learning the surface information in antigen and antibody binding, and the prediction efficiency and accuracy are improved.
Owner:SHANGHAI MOLECULAR HEART INTELLIGENT TECH CO LTD

Fully human monoclonal antibody targeting rabies virus G protein epitope and application thereof

The present invention provides a rabies virus G protein antigen epitope targeting completely human monoclonal antibody and applications thereof, the completely human monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP, and the light chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP. The amino acid sequences of the three complementary determining regions of the light chain variable region are respectively as follows: QGISND, ATS and LQDYEFPLT. The fully human monoclonal antibody has efficient and broad-spectrum anti-rabies virus neutralizing activity, is high in expression, fully human-derived and good in stability, and can be used for preparing rabies virus detection products or drugs for preventing and treating rabies.
Owner:WUHAN UNIV

T cell epitope high-throughput screening method and device based on deep learning framework

The invention relates to the technical field of biological information prediction, and provides a T cell epitope high-throughput screening method and device based on a deep learning framework, and the method comprises the steps: extracting target input data according to an input T cell receptor sequence and an antigen sequence; wherein the target input data comprises a T cell receptor CDR3 beta sequence and at least one antigen epitope peptide fragment sequence; inputting the target input data into a pre-constructed prediction model to obtain a prediction result; and screening according to the prediction result to obtain a screening result. According to the method, a T cell receptor sequence and an antigen sequence which are not subjected to standardization treatment are allowed to be input, the CDR3 beta sequence can be efficiently extracted, then the binding activity prediction work is effectively carried out, the data preprocessing workload of an operator is reduced while the universality and the stability are improved, and the detection efficiency is improved. Meanwhile, the T cell receptor and epitope binding probability is predicted based on the deep neural network, and screening work is effectively completed.
Owner:SUZHOU CHUANGTENG SOFTWARE CO LTD

Preparation method of oxidized low-density lipoprotein quality control product prepared based on novel antigen

The invention discloses a preparation method of an oxidized low-density lipoprotein quality control product prepared on the basis of a novel antigen, and the method comprises the following steps: constructing an oxidized low-density lipoprotein model, carrying out molecular dynamics simulation by setting a plurality of groups of simulation conditions to calculate a stability index, and determining an optimal antigen preparation condition; acquiring antigen epitope data, and constructing a feature vector, so as to predict and screen an optimal antigen epitope by utilizing a machine learning algorithm; and based on a target cross-linking strategy, combining the oxidized low-density lipoprotein prepared under the optimal antigen preparation condition with the optimal epitope to obtain a target quality control product. According to the scheme, the preparation efficiency and quality can be improved.
Owner:XIAN GOLDMAG NANOBIOTECH

Antigen epitope peptide related to connexin and application of antigen epitope peptide

The invention provides an antigen epitope peptide related to connexin and application of the antigen epitope peptide. The connexin antigen epitope peptide disclosed by the invention is selected from (1) a polypeptide with an amino acid sequence as shown in SEQ ID NO: 14; and (2) a polypeptide which is derived from (1) by substituting, deleting or adding 1-2 amino acids in the amino acid sequence of SEQ ID NO: 14 and retains the binding capacity with a connexin antibody. According to the present invention, the new connexin antigenic peptide fragment sequence is identified for the first time, such that the existing autoantigen epitope map is expanded, and more importantly, the molecular basis is provided for the development of the clinical detection method with high diagnosis sensitivity and high specificity, such that the pathological mechanism of MG can be further improved, and the application prospect is broad. And new auxiliary diagnosis means and treatment targets are provided for antibody negative MG patients.
Owner:XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI

Method for screening potential neoantigen of tumor from transposition element

The invention provides a method for screening a potential neoantigen of a tumor from a transposon element. The method comprises the following steps: collecting tumor tissue transcriptome sequencing data and normal tissue transcriptome sequencing data; identifying a TE transcript new type TEtrans based on a TE splicing event; performing feature analysis on the TEtrans; the TEtrans with the potential coding capability is screened out; and identifying the new antigen epitope peptide from the TEtrans: hydrolyzing all open reading frames of the to-be-selected TEtrans into 9 peptides which are mutually overlapped, removing annotated peptide fragments contained in Uniprot, defining the new antigen epitope peptide from the TEtrans according to allele typing of a tumor sample, further comparing the new antigen from the TEtrans with three common new antigens from genomic variation sources, and identifying the new antigen from the TEtrans. And screening to obtain the tumor potential new antigen. According to the invention, a brand new intergene region TE source transcript is successfully identified, and the transcript can be uniquely positioned and accurately quantified, so that a tumor specific transcript is screened as a potential tumor new antigen, and the method has huge potential in the aspect of developing tumor new antigen vaccines, especially tumors with low mutation load.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Goose astrovirus type 2 monoclonal antibody and antigen epitope peptide thereof

The invention discloses a type 2 GAstV capsid protein monoclonal antibody and an antigen epitope peptide of the type 2 GAstV capsid protein monoclonal antibody. The monoclonal antibody is prepared by immunizing a mouse with capsid protein GAstV Cap of the type 2 goose astrovirus as an antigen, and is named as 1F1; the monoclonal antibody 1F1 comprises a heavy chain variable region and a light chain variable region, and the amino acid sequences of the heavy chain variable region and the light chain variable region are sequentially shown as SEQ ID No.3 and SEQ ID No.5. In order to determine the B cell antigen epitope of the screened monoclonal antibody, the invention also constructs a GAstV Cap truncated fusion protein, and the antigen recognition epitope is determined through indirect ELISA and Western blotting tests, so that screening is carried out step by step until the shortest linear epitope recognized by the monoclonal antibody is determined, and the amino acid sequence of the shortest linear epitope is shown as SEQ ID No.10. Therefore, the monoclonal antibody and the antigen epitope of the monoclonal antibody can be applied to research on structures and functions of GAstV capsid proteins and preparation of serological diagnostic tools and epitope vaccines.
Owner:SICHUAN AGRI UNIV

Porcine reproductive and respiratory syndrome virus M protein antigen epitope peptide and monoclonal antibody and application thereof

The invention discloses a porcine reproductive and respiratory syndrome virus M protein antigen epitope peptide and a monoclonal antibody thereof. The amino acid sequence of the antigen epitope peptide is as shown in SEQ ID No. 11; the heavy chain variable region of the monoclonal antibody comprises CDR1-3 as shown in SEQ ID No.1 to SEQ ID No.3; the light chain variable region comprises CDR1-3 as shown in SEQ ID No. 4 to 6; the monoclonal antibody reacts with a plurality of PRRSV strains such as HP-PRRSV, NADC30PRRSV, NADC34PRRSV and the like, and the conservative property is good; the antibody can be obtained by biological means such as conventional genetic engineering, and the problem that the genetic sequence of the antibody is easy to lose due to long-term cryopreservation of traditional hybridoma cells is avoided; optimization of the antibody on the gene or protein level is facilitated, and the specificity and affinity of the antibody are further improved.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Disease marker epitope prediction and antibody screening method

The invention provides a disease marker epitope prediction and antibody screening method, which belongs to the technical field of disease markers, and comprises the following steps: firstly, establishing a training data set containing a known antigen-antibody compound structure and disease tissue expression data; and obtaining target protein sequence information through liquid chromatography-mass spectrometry analysis and carrying out sequence comparison. And then a deep convolutional neural network is utilized to extract sequence features, and surface exposure sites are identified by combining secondary structure prediction and solvent accessibility analysis. After the features are integrated with sequence evolution conservative properties, a prediction model is constructed by using a random forest classifier. The method comprises the following steps: carrying out molecular dynamics simulation on a prediction result, screening first 10% of candidate sequences through a comprehensive scoring function and K-means clustering, and finally determining an antigen epitope sequence with the strongest binding activity through verification of an antigen chip and a fluorescence labeled antibody system, so that the technical problem that specific antigen epitopes are difficult to accurately predict and recognize in the prior art is solved.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD

Metrosporidium tenella surface antigen and application thereof in early ELISA (enzyme-linked immuno sorbent assay) detection of metrosporidium tenella

The invention discloses a surface antigen gene StSAG1 of Sarcocystis tenella, the nucleotide sequence of the surface antigen gene StSAG1 is as shown in SEQ ID NO: 1, and according to the analysis result of protein antigenicity and antigen epitope, the 686 bp-1175 bp segment of the StSAG1 gene is selected to construct a recombinant protein expression vector and engineering bacteria; the antigen disclosed by the invention has very strong antigenicity and specificity, and can be subjected to effective antigen-antibody reaction with an antibody generated in serum after sheep (Ovis aries) is infected with sarcosporidium tenella, so that diagnosis is realized; low-titer antibodies can be detected two weeks after infection, and the detection window period is obviously advanced; by adopting the ELISA detection method, a visual result can be directly obtained. The method breaks through the limitation of an infection window period, has the advantages of low cost, high sensitivity, simplicity and convenience in operation, no need of expensive instruments and analysis and the like, is suitable for field detection in primary laboratories and pastures, and is beneficial to industrial production and market popularization and application.
Owner:YUNNAN UNIV +2

Tumor antigen epitope coding mRNA vaccine and preparation method and application thereof

The invention belongs to the technical field of tumor vaccines, and particularly relates to an mRNA (messenger Ribonucleic Acid) vaccine for coding tumor antigen epitopes as well as a preparation method and application thereof. In order to overcome the defect of immune escape caused by insufficiency or loss of a single antigen, the invention provides an mRNA vaccine capable of simultaneously coding a plurality of tumor antigen epitopes, and the tumor antigen epitopes are selected from high-frequency mutation epitopes of human tumor driving genes, such as G12D, G12V and G12C mutations of RAS genes; the antigenic epitopes can be used for preparing antigenic epitopes related to common viruses of human tumors, such as HPV16E6 / E7, EBV LAMP1 or CMV pp65, and tumor high-expression carcino-embryonic antigen gene epitopes, such as MAGE-A4, NY-ESO-1, WT1, and the like. The mRNA vaccine is obtained by serially expressing a plurality of tumor antigen epitopes and encapsulating and delivering lipid nanoparticles. Experiments prove that the compound can effectively prevent and treat various tumors and has a wide application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Hepatitis B virus specific TCR combination and application

The invention relates to the field of immunology, and particularly discloses a hepatitis B virus specific TCR combination and application, the hepatitis B virus specific TCR combination is used for recognizing HBV antigen epitopes, the hepatitis B virus specific TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.
Owner:THE THIRD PEOPLES HOSPITAL OF SHENZHEN

RSV nanoparticle vaccine and preparation method therefor

PCT designated stageWO2025179940A1DepsipeptidesAntiviralsAntigen epitopeF protein
The present invention relates to the technical field of biomedicine. Specifically provided are a respiratory syncytial virus (RSV) Pre-F recombinant protein nanoparticle vaccine and a preparation method therefor. By performing amino acid mutation on an RSV Pre-F protein, and performing fusion expression on the mutated Pre-F protein and ferritin particles in eukaryotic cells, PreF-Ferritin fusion protein nanoparticles, in which eight Pre-F protein trimers are densely displayed on the surface of each ferritin particle, are obtained. By stabilizing and exposing antigen epitopes required to be displayed and disrupting or masking unrequired antigen epitopes, the PreF-Ferritin fusion protein nanoparticles effectively improve the immunogenicity and the production stability of the antigen. Experiments show that: when the PreF-Ferritin fusion protein is injected into mice, high-titer protective sera can be acquired, and the mice sera can yield relatively high neutralizing titers against RSV.
Owner:UNIVERSALVAX BIOTECHNOLOGIES (TAIZHOU) CO LTD

Methods and compositions for discovery of receptor-ligand specificity by engineered cell entry

The present disclosure relates to systems, methods and compositions for decoding ligand-receptor interactions, for delivering nucleic acids and proteins into target cells and for performing single cell multiomics. Disclosed are engineered lentiviruses displaying ligands that deliver cargo into target cells upon cognate receptor-ligand interaction. Also disclosed are compositions and methods including pMHC or antigen epitopes displaying lentiviruses for identifying pMHC / T-cell receptors and antigen / B-cell receptor interactions.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Avian infectious bronchitis virus antigen epitope fusion peptide

The invention provides an infectious bronchitis virus antigen epitope fusion peptide, and the prepared antigen epitope fusion peptide can be used for preparing an antibody and can also be used as a coating antigen for preparing an indirect ELISA detection product. The amino acid sequence of the provided epitope fusion peptide is SEQ ID NO: 4. After antigen epitope analysis is performed on S1 protein of an infectious bronchitis virus strain through bioinformatics software, a plurality of antigen epitopes are fused to obtain the antigen epitope fusion peptide. Specificity tests show that the prepared antigen epitope fusion peptide is a coating antigen, does not have cross reaction with positive serum of other common pathogens, and only has good reaction with positive serum of GI-19 type IBV, that is, the antigen epitope fusion peptide has good serotype specificity as a detection antigen, and has small cross reaction with non-GI-19 type IBV antibody.
Owner:CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENT

Biregulin recombinant vaccine and application thereof in pulmonary fibrosis treatment

The invention relates to the technical field of immunotherapy, in particular to a regulatory protein recombinant vaccine and application thereof in pulmonary fibrosis treatment. The vaccine contains polypeptide of amphiregulin antigen epitopes, and the amino acid sequence of the vaccine is shown as SEQ ID No. 1. A research result shows that the recombinant vaccine can effectively induce generation of a specific antibody aiming at the AREG protein in a mouse body, so that secretion of the AREG protein and activation of downstream receptors of the AREG protein in the pulmonary fibrosis process are inhibited. By reducing collagen deposition in lung tissue and reducing tissue structure damage, the recombinant vaccine significantly reduces gene expression of fibrosis-related protein, recovers lung functions of pulmonary fibrosis model mice, and inhibits further development of diseases. In addition, the recombinant vaccine can be administered in an aerosol inhalation mode, and has broad-spectrum, efficient and long-term stable expression and good safety. The invention provides a brand-new targeted therapy means for clinical prevention and treatment of pulmonary fibrosis, and shows a wide application prospect.
Owner:QINGDAO UNIV

Porcine delta coronavirus spike protein monoclonal antibody, antigen epitope peptide and application

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.
Owner:YANGZHOU UNIV

Fusion protein, base editing system for realizing protein multimerization and application

The invention belongs to the technical field of gene editing, and discloses a fusion protein, a base editing system for realizing protein multimerization and application. The fusion protein provided by the invention is a Cas9 protein in which antigen epitopes are embedded or replaced; the antigen epitope is an antigen epitope in a protein collection system; the antigen epitope can realize multimerization of the fusion protein. The base editor system comprises the fusion protein and an editing enzyme fusion protein. The editing enzyme fusion protein comprises an antibody of the antigen epitope and editing enzyme. The base editor system disclosed by the invention has the characteristics of a base editing platform which can be modularized, multimerized, programmable and extensible, and brings more possibilities and selection capabilities to the field of gene editing. The base editor system can be applied to gene editing, including application in the fields of basic research, gene therapy, animal living body editing, agricultural breeding and the like.
Owner:ZHUHAI SHU TONG MEDICAL TECH CO LTD

Recombinant humanized collagen as well as synthesis method and application thereof

The invention discloses recombinant humanized XVII type and recombinant humanized I type collagen sequences as well as a synthesis method and application thereof, the recombinant humanized collagen comprises one or more functional sequences in cell integrin binding sites such as R / KGD, GER / K, GVMGFP and DGEA, the molecular weight is 6-14 kDa, and the recombinant humanized collagen simultaneously surrounds an isoelectric point, has hydrophilicity and hydrophobicity, and can be used for preparing the recombinant humanized collagen. Reasonable design is carried out on information such as an antigen epitope, GXY sequence stability, protease degradation sites and the like, so that the recombinant humanized collagen has relatively good stability and also has biological activity of promoting cell proliferation and resisting wrinkles and tightening.
Owner:CHANGZHOU INST OF MATERIA MEDICA

Monkey pox virus nano-vaccine based on STING agonist and silicon nano-particles as well as preparation method and application of monkey pox virus nano-vaccine

The invention relates to a monkey pox virus nano vaccine based on an STING agonist and silicon nanoparticles as well as a preparation method and application of the monkey pox virus nano vaccine. The nano vaccine comprises a monkey pox virus antigen, the silicon nanoparticles and the STING agonist, the monkey pox virus antigen is combined to the surface of the silicon nanoparticle through a DogTag-DogCatcher system; the STING agonist is connected to the surface of the monkey pox virus antigen. The monkey pox virus antigen is covalently coupled with the silicon nanoparticles, and the antigen is displayed on the surfaces of the particles in a specific spatial orientation manner, so that the multivalence and accessibility of the antigen are enhanced, the shielding effect of the silicon nanoparticles on epitopes of the antigen is reduced, and the immune response induced by the vaccine is higher than that of a monomer immunogen protein.
Owner:INSTITUTE OF PROCESS ENGINEERING CHINESE ACADEMY OF SCIENCES

Specific nano antibody targeting bovine TLR7 protein as well as screening method and application of specific nano antibody

The invention belongs to the technical field of molecular biology, and particularly discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The nano antibody can be specifically combined with a B cell antigen epitope of bovine TLR7 protein, and the B cell antigen epitope is selected from SEQ ID NO: 1 and / or SEQ ID NO: 2. The invention discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The specific nano antibody targeting bovine TLR7 protein is high in stability and specificity and has super-strong affinity.
Owner:ANHUI AGRICULTURAL UNIVERSITY +1

Antigen epitope polypeptide for detecting antibody generated by brucella infection and application of antigen epitope polypeptide

The invention discloses an antigen epitope polypeptide for detecting an antibody generated by brucella infection and application of the antigen epitope polypeptide. The amino acid sequence of the antigen epitope polypeptide for detecting the antibody generated by Brucella infection comprises sequences as shown in SEQ ID NO: 1 to SEQ ID NO: 3. The antigen epitope polypeptide and the kit can rapidly detect an antibody generated by brucella infection in a biological sample, high sensitivity and high specificity can be achieved at the same time, the polypeptide and the kit can improve the specificity and sensitivity of human brucellosis diagnosis so as to guide brucellosis treatment, and the time cost is low.
Owner:SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI

Preparation method of macaca fascicularis liver tissue single-cell suspension

The invention belongs to the technical field of biology, and particularly relates to a preparation method of macaca fascicularis liver tissue single-cell suspension. The method comprises the following steps: cleaning macaca fascicularis liver tissues with a pre-cooling buffer solution, and processing into tissue fragments; mixing the tissue fragments with a digestion solution, wherein the digestion solution comprises collagenase I with the final concentration of 1 + / -0.2 mg / ml, collagenase II with the final concentration of 1 + / -0.2 mg / ml, bovine serum albumin with the final concentration of 0.04 + / -0.01% (w / v), DNase I with the final concentration of 10 + / -2 U / ml and the balance of a buffer solution; oscillating and incubating for 30 + / -10min under the conditions of 37 + / -2 DEG C and 150 + / -50rpm, and performing tissue digestion; centrifuging the digested suspension, removing the supernatant, resuspending with a buffer solution, and filtering with a cell sieve to obtain a single-cell primary suspension; and carrying out red blood cell lysis, washing and resuspension on the single-cell primary suspension to prepare the cynomolgus monkey liver tissue single-cell suspension. The method significantly improves the tissue dissociation efficiency, reduces cell adhesion and fragments, effectively protects cell surface antigen epitopes, and has the advantages of simple operation, economy and high efficiency.
Owner:JOINN LAB (SUZHOU) INC